{"id":"ethinyl-estradiol-etonogestrel-vaginal-ring","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vaginal irritation or discomfort"},{"rate":null,"effect":"Breast tenderness"},{"rate":null,"effect":"Mood changes"},{"rate":null,"effect":"Breakthrough bleeding"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ethinyl estradiol is a synthetic estrogen and etonogestrel is a synthetic progestin. Together they inhibit the luteinizing hormone (LH) and follicle-stimulating hormone (FSH) surges needed for ovulation. The progestin component also thickens cervical mucus to impede sperm transport and alters the endometrium to prevent implantation. The vaginal ring formulation provides sustained hormone release over a 3-week cycle.","oneSentence":"Ethinyl estradiol and etonogestrel work together as a combined hormonal contraceptive that suppresses ovulation and alters cervical mucus to prevent pregnancy.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:54.702Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception in women of reproductive age"}]},"trialDetails":[{"nctId":"NCT04257500","phase":"PHASE4","title":"Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/Obese Women With PCOS","status":"COMPLETED","sponsor":"Andrea Roe, MD, MPH","startDate":"2020-09-03","conditions":"Polycystic Ovary Syndrome","enrollment":22},{"nctId":"NCT02367846","phase":"PHASE4","title":"Assessing the Impact of Contraceptives on Bone Health Using 41Ca","status":"ACTIVE_NOT_RECRUITING","sponsor":"Penn State University","startDate":"2015-01","conditions":"Other Disorders of Bone Development and Growth","enrollment":6},{"nctId":"NCT05994599","phase":"PHASE1","title":"Comparative Bioavailability Study of Ethinyl Estradiol/Etonogestrel Vaginal Ring","status":"COMPLETED","sponsor":"Evestra Inc.","startDate":"2023-07-29","conditions":"Healthy Women, Female, Contraception","enrollment":36},{"nctId":"NCT01277211","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-09-19","conditions":"Contraception","enrollment":983},{"nctId":"NCT01709318","phase":"PHASE2","title":"A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-12-12","conditions":"Contraception","enrollment":666},{"nctId":"NCT01490190","phase":"PHASE4","title":"Study of the Use of a Contraceptive Vaginal Ring (NuvaRing) in Normal Daily Practice in Indian Women (P07733)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-12-26","conditions":"Contraception","enrollment":252},{"nctId":"NCT02616146","phase":"PHASE3","title":"Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2015-12-01","conditions":"Contraception","enrollment":2016},{"nctId":"NCT04423068","phase":"EARLY_PHASE1","title":"Inpatient Adolescent Contraception","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2020-12-10","conditions":"Pregnancy Related, Contraception, Contraceptive Usage","enrollment":25},{"nctId":"NCT05360550","phase":"PHASE2","title":"A Study to Evaluate the Effect of a Contraceptive Vaginal Ring LSP- 5415 on Ovarian Function in Healthy Adult Females","status":"COMPLETED","sponsor":"Lupin Research Inc","startDate":"2022-07-05","conditions":"Pregnancy Prevention","enrollment":26},{"nctId":"NCT05360576","phase":"PHASE2","title":"An Open-label, Randomized, 2-Period, Crossover, Pharmacokinetics Study","status":"COMPLETED","sponsor":"Lupin Research Inc","startDate":"2022-02-24","conditions":"Pregnancy Prevention","enrollment":40},{"nctId":"NCT01044056","phase":"PHASE4","title":"A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) (Study 34237 (P06650)) (COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-03","conditions":"Contraception","enrollment":24},{"nctId":"NCT02367833","phase":"PHASE4","title":"Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis","status":"COMPLETED","sponsor":"Penn State University","startDate":"2015-01","conditions":"Bone; Disorder, Development and Growth","enrollment":60},{"nctId":"NCT02404038","phase":"NA","title":"A Study to Evaluate the Acceptability and Preference for Contraceptive Options as Proxy for HIV Prevention Methods","status":"UNKNOWN","sponsor":"Desmond Tutu HIV Centre","startDate":"2015-07","conditions":"HIV","enrollment":131},{"nctId":"NCT01903031","phase":"PHASE2","title":"Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2014-12-30","conditions":"HIV-1 Infection","enrollment":84},{"nctId":"NCT03120728","phase":"PHASE4","title":"Application for the Etonogestrel/Ethinyl Estradiol Ring","status":"UNKNOWN","sponsor":"University of Southern California","startDate":"2017-07-10","conditions":"Emergency Contraception, Healthy, Reproductive Age Women","enrollment":36},{"nctId":"NCT02529683","phase":"NA","title":"Study of Nuvaring Acceptability, Adherence and Biological Effects Among HIV-negative Women in Kenya","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-04","conditions":"Hormonal Contraception","enrollment":200},{"nctId":"NCT01638767","phase":"PHASE4","title":"NuvaRing Versus Marvelon in the Coordination of In Vitro Fertilization Cycles","status":"TERMINATED","sponsor":"Clinique Ovo","startDate":"2012-07","conditions":"Infertility","enrollment":7},{"nctId":"NCT01813162","phase":"PHASE1","title":"In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products","status":"COMPLETED","sponsor":"CONRAD","startDate":"2013-12","conditions":"HIV Prevention","enrollment":101},{"nctId":"NCT01796613","phase":"PHASE2, PHASE3","title":"Safety and Acceptability of Vaginal Rings That Protect Women From Unintended Pregnancy","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2013-06","conditions":"Contraception","enrollment":120},{"nctId":"NCT00612508","phase":"NA","title":"Hormonal Contraception and Vaginal Health","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2007-05","conditions":"Contraceptive Usage, Vaginal Epithelial Disruption","enrollment":14},{"nctId":"NCT01448291","phase":"PHASE4","title":"Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers","status":"UNKNOWN","sponsor":"Eastern Virginia Medical School","startDate":"2011-10","conditions":"Vaginosis, Bacterial","enrollment":30},{"nctId":"NCT01087879","phase":"NA","title":"The Effect of Hormonal Contraceptives on Androgens and Glucose Metabolism","status":"COMPLETED","sponsor":"University of Oulu","startDate":"2007-10","conditions":"Contraception","enrollment":45},{"nctId":"NCT01384331","phase":"PHASE4","title":"New Treatments for Troublesome Bleeding in Implanon Users","status":"UNKNOWN","sponsor":"Family Planning Association New South Wales","startDate":"2011-07","conditions":"Menstrual Problem","enrollment":200},{"nctId":"NCT00475553","phase":"NA","title":"Management of Breakthrough Bleeding During Extended Therapy Use With NuvaRing®","status":"COMPLETED","sponsor":"Scott and White Hospital & Clinic","startDate":"2006-05","conditions":"Breakthrough Bleeding, Breakthrough Spotting","enrollment":75},{"nctId":"NCT00269620","phase":"PHASE4","title":"PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2005-06","conditions":"Contraception","enrollment":500}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"NAUSEA"},{"count":2,"reaction":"PRODUCT SUBSTITUTION ISSUE"},{"count":1,"reaction":"ABDOMINAL PAIN"},{"count":1,"reaction":"DECREASED APPETITE"},{"count":1,"reaction":"DEPRESSION"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"FUNGAL INFECTION"},{"count":1,"reaction":"HEADACHE"},{"count":1,"reaction":"IMPAIRED WORK ABILITY"}],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nuvaring"],"phase":"marketed","status":"active","brandName":"ethinyl estradiol/etonogestrel vaginal ring","genericName":"ethinyl estradiol/etonogestrel vaginal ring","companyName":"University of Pittsburgh","companyId":"university-of-pittsburgh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ethinyl estradiol and etonogestrel work together as a combined hormonal contraceptive that suppresses ovulation and alters cervical mucus to prevent pregnancy. Used for Contraception in women of reproductive age.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}